SEC Filings
Novartis Raises Kesimpta Sales Potential To $8 Billion And Extends Its Growth Outlook
The drugmaker also lifted forecasts for Scemblix and Leqvio as it looks to grow through patent losses and trial setbacks.
Novartis (NVS) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The drugmaker also lifted forecasts for Scemblix and Leqvio as it looks to grow through patent losses and trial setbacks.
Earnings
Vas Narasimhan says the modeling is done, even after a $1.9 billion partial write-down of a neuromuscular drug.
Earnings
CEO Vas Narasimhan says the company counts only indications that have read out positive in late-stage trials, so more upside waits.
Earnings
The drugmaker now expects 2026 core operating income to hold flat or grow slightly, even as a $1.9 billion write-down hit reported profit.